PrecisionLife CEO, Steve Gardner, is speaking at the 32nd Annual Precision Med Tri-Con in San Diego from 11-13 March 2025.
Improving the Prediction, Treatment, & Prevention of Chronic Diseases
10:50-11:20AM, Tuesday 11 March | San Diego, CA
Track: AI in Precision Medicine
Session: Clinical Implementation of AI in Precision Medicine
Chronic diseases affect billions of lives and account for over 80% of healthcare spending but lack effective diagnosis and treatment options due to the complex biology that underpins them. This presentation will discuss an AI-driven precision medicine approach that is enabling new understanding of the mechanisms that cause chronic diseases. I will demonstrate how these insights are being used to predict lifetime disease risk in patients, diagnose major diseases earlier with greater accuracy, identify effective treatments targeting the biological drivers of disease, and prevent the onset and progression of diseases to improve health outcomes and reduce health costs.
Omics, Data, and AI in Precision Medicine
12PM, Wednesday 12 March | San Diego, CA
- Steve Gardner, CEO and Co-founder, PrecisionLife
- Kyle Farh, Vice President & Distinguished Scientist, Artificial Intelligence Lab, Illumina
- Eleanor Howe, Founder & CEO, Diamond Age Data Science
- Ryan Taft, Senior Vice President, Genomics R&D, Tempus AI
The promise of AI for understanding disease biology, drug discovery, and diagnostics hinges on the rise of large omics datasets. In this panel, experts from Tempus AI, Illumina, and PrecisionLife will explore the key considerations for omics data generation and curation. They'll also discuss crucial data challenges, such as accessibility and representation, that might prevent AI from reaching its full potential in precision medicine.
About PrecisionLife
PrecisionLife is a clinical-stage precision medicine company creating better diagnostic tools and more personalized treatment options to predict, treat, and prevent complex chronic diseases, which account for over 80% of healthcare spending. Their growing prevalence is making healthcare increasingly unaffordable in all major economies.
The AI-led PrecisionLife platform is unparalleled in its understanding of disease biology – identifying the underlying causes of disease and biomarkers to stratify patients by molecular mechanism for the first time in complex conditions. This enables us to accurately link individuals to the drug targets, clinical trials and treatments that will benefit them – leading to earlier, more accurate and effective disease prediction, diagnosis, treatment, and prevention.
Our unique disease insights and precision medicine tests hold the key to increasing the rate of success in drug development, reducing the global burden of chronic diseases, and improving health for billions of people.
